Next-generation SIGNA MRI gains FDA nod, sharpening GE HealthCare’s imaging strategy
GE HealthCare secures FDA clearance for next-generation SIGNA MRI. Explore clinical impact, workflow gains, and market implications.
GE HealthCare secures FDA clearance for next-generation SIGNA MRI. Explore clinical impact, workflow gains, and market implications.
Medtronic wins FDA clearance for Stealth AXiS in spine robotics. Explore what this integrated platform means for workflow, data, and adoption.
Aesyra’s AesyBite Active reduced sleep bruxism by over 60% in trial. Find out what this could mean for digital therapeutics and FDA approval in 2026.
Aidoc’s CARE AI gets FDA clearance for 14-condition CT triage. Find out how it may reshape emergency imaging, hospital workflows, and clinical AI governance.
FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.
Vista AI, a U.S.-based medical imaging software company specializing in AI-powered MRI automation, has raised $29.5 million in Series B financing to accelerate its product roadmap and scale adoption across U.S. hospitals and imaging centers. The funding round, announced on January 14, 2026, includes strategic investments from leading health systems such as Cedars-Sinai Health System,
Medtronic’s MiniMed Go earns FDA clearance. Learn how it could reshape insulin injection therapy by combining smart pens, CGM insights, and dose algorithms.
Avatar Medical is set to introduce Eonis Vision, a glasses-free 3D medical imaging system, at CES 2026. The product, developed in collaboration with Belgian display specialist Barco and powered by high-performance Dell hardware, is aimed at enhancing the clarity of doctor–patient communication. While the original Avatar Medical Vision software is already FDA-cleared, the updated version
RevBio Inc. has received approval from the United States Food and Drug Administration to initiate a pilot clinical trial evaluating TETRANITE, its regenerative bone adhesive, for dental ridge augmentation procedures. The trial will examine whether the product can eliminate the need for membranes, meshes, tacks, and fixation screws—elements that have traditionally been considered essential for
Kallisio has begun clinical implementation of its FDA-cleared Stentra system at Stanford Health Care, marking the first reported integration of the patient-specific intraoral device into a major U.S. hospital’s workflow for head and neck cancer radiation therapy. The system, which received 510(k) clearance in January 2024, enables individualized immobilization of oral structures during intensity-modulated radiation